Hai-Jie Hu1, Yan-Wen Jin1, Rong-Xing Zhou1, Wen-Jie Ma1, Qin Yang1, Jun-Ke Wang1, Fei Liu1, Nan-Sheng Cheng1, Fu-Yu Li2. 1. Department of Biliary Surgery, West China Hospital of Sichuan University, Chengdu, 610041, Sichuan Province, China. 2. Department of Biliary Surgery, West China Hospital of Sichuan University, Chengdu, 610041, Sichuan Province, China. lfy_74@hotmail.com.
Abstract
BACKGROUND: We aimed to examine whether inflammation-based prognostic scores could predict tumor resectability in a cohort of hilar cholangiocarcinoma patients with preoperative hyperbilirubinemia. We also sought to investigate the prognostic factors associated with overall survival in the subgroup of patients with an R0 resection. METHODS: A total of 173 patients with potentially resectable hilar cholangiocarcinoma, as judged by radiological examinations, were included. The potential relationship of the Glasgow prognostic score (GPS), modified GPS, platelet lymphocyte ratio (PLR), neutrophil lymphocyte ratio (NLR), prognostic nutritional index (PNI), and prognostic index (PI) with tumor resectability were investigated using univariate and multivariate analysis. RESULTS: Among the 173 patients, 134 had R0 resection margins. Univariate analysis identified that patients with PLR ≥ 150, NLR ≥ 3, PNI ≥ 45, GPS (0.1/2), modified GPS (0.1/2), preoperative CA 125 > 35 U/mL, and a tumor size ≥ 3 cm were more likely to have unresectable tumors. Multivariate analysis indicated that tumor size ≥ 3 cm (OR = 2.422, 95% CI: 1.053-5.573; P = 0.037), PLR ≥ 150 (OR = 3.324, 95% CI: 1.143-9.667; P = 0.027), preoperative CA 125 > 35 U/mL (OR = 3.184, 95% CI: 1.316-7.704; P = 0.010), and GPS (0.1/2) (OR = 2.440, 95% CI: 1.450-4.107; P = 0.001) were independent factors associated with tumor resectability. In selected patients with an R0 resection in this cohort, nodal status (P = 0.010) and tumor differentiation (P = 0.025) were predictive of poor survival outcome. CONCLUSION: Patients with higher GPS, CA 125, and PLR levels, and a larger tumor size, tend to have unresectable tumors even if they were judged as potentially resectable using preoperative radiological examinations.
BACKGROUND: We aimed to examine whether inflammation-based prognostic scores could predict tumor resectability in a cohort of hilar cholangiocarcinomapatients with preoperative hyperbilirubinemia. We also sought to investigate the prognostic factors associated with overall survival in the subgroup of patients with an R0 resection. METHODS: A total of 173 patients with potentially resectable hilar cholangiocarcinoma, as judged by radiological examinations, were included. The potential relationship of the Glasgow prognostic score (GPS), modified GPS, platelet lymphocyte ratio (PLR), neutrophil lymphocyte ratio (NLR), prognostic nutritional index (PNI), and prognostic index (PI) with tumor resectability were investigated using univariate and multivariate analysis. RESULTS: Among the 173 patients, 134 had R0 resection margins. Univariate analysis identified that patients with PLR ≥ 150, NLR ≥ 3, PNI ≥ 45, GPS (0.1/2), modified GPS (0.1/2), preoperative CA 125 > 35 U/mL, and a tumor size ≥ 3 cm were more likely to have unresectable tumors. Multivariate analysis indicated that tumor size ≥ 3 cm (OR = 2.422, 95% CI: 1.053-5.573; P = 0.037), PLR ≥ 150 (OR = 3.324, 95% CI: 1.143-9.667; P = 0.027), preoperative CA 125 > 35 U/mL (OR = 3.184, 95% CI: 1.316-7.704; P = 0.010), and GPS (0.1/2) (OR = 2.440, 95% CI: 1.450-4.107; P = 0.001) were independent factors associated with tumor resectability. In selected patients with an R0 resection in this cohort, nodal status (P = 0.010) and tumor differentiation (P = 0.025) were predictive of poor survival outcome. CONCLUSION:Patients with higher GPS, CA 125, and PLR levels, and a larger tumor size, tend to have unresectable tumors even if they were judged as potentially resectable using preoperative radiological examinations.
Authors: J I Tsao; Y Nimura; J Kamiya; N Hayakawa; S Kondo; M Nagino; M Miyachi; M Kanai; K Uesaka; K Oda; R L Rossi; J W Braasch; J M Dugan Journal: Ann Surg Date: 2000-08 Impact factor: 12.969
Authors: F Kimura; M Miyazaki; T Suwa; T Sugiura; T Shinoda; H Itoh; K Nagakawa; S Ambiru; H Shimizu; H Yoshitome Journal: J Gastroenterol Hepatol Date: 2001-04 Impact factor: 4.029
Authors: Campbell S D Roxburgh; Jonathan M Salmond; Paul G Horgan; Karin A Oien; Donald C McMillan Journal: Ann Surg Date: 2009-05 Impact factor: 12.969
Authors: P Neuhaus; S Jonas; W O Bechstein; R Lohmann; C Radke; N Kling; C Wex; H Lobeck; R Hintze Journal: Ann Surg Date: 1999-12 Impact factor: 12.969
Authors: Julie K Heimbach; Gregory J Gores; Michael G Haddock; Steven R Alberts; Rachel Pedersen; Walter Kremers; Scott L Nyberg; Michael B Ishitani; Charles B Rosen Journal: Transplantation Date: 2006-12-27 Impact factor: 4.939
Authors: Jan Harder; Oliver Kummer; Manfred Olschewski; Florian Otto; Hubert Erich Blum; Oliver Opitz Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-10 Impact factor: 4.254
Authors: Alexander J C IJitsma; Bart M G Appeltans; Koert P de Jong; Robert J Porte; Paul M J G Peeters; Maarten J H Slooff Journal: J Gastrointest Surg Date: 2004 Sep-Oct Impact factor: 3.267
Authors: Christoph W Michalski; Jörg Kleeff; Jeannine Bachmann; Jaber Alkhatib; Mert Erkan; Irene Esposito; Ulf Hinz; Helmut Friess; Markus W Büchler Journal: Ann Surg Oncol Date: 2007-10-18 Impact factor: 5.344
Authors: Dong Liu; Lara R Heij; Zoltan Czigany; Edgar Dahl; Marcel den Dulk; Sven A Lang; Tom F Ulmer; Ulf P Neumann; Jan Bednarsch Journal: Sci Rep Date: 2022-07-25 Impact factor: 4.996
Authors: Dong Liu; Zoltan Czigany; Lara R Heij; Stefan A W Bouwense; Ronald van Dam; Sven A Lang; Tom F Ulmer; Ulf P Neumann; Jan Bednarsch Journal: Cancers (Basel) Date: 2022-01-16 Impact factor: 6.639